Late response to cyclosporine in refractory thrombotic thrombocytopenic purpura

被引:11
作者
Nosari, A [1 ]
Bernuzzi, P [1 ]
Corneo, R [1 ]
Pungolino, E [1 ]
Muti, G [1 ]
Rossi, V [1 ]
Morra, E [1 ]
机构
[1] Osped Niguarda Ca Granda, Dept Oncol & Hematol, Hematol Unit, I-20162 Milan, Italy
关键词
thrombotic thrombocytopenic purpura; refractory; cyclosporine;
D O I
10.1007/BF02982800
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Plasma exchange (PEX) with fresh frozen plasma, usually in association with steroid therapy. has been shown to be the firstline treatment of thrombotic thrombocytopenic purpura. It works by removing ultralarge von Willebrand factor (vWF) multimers and inhibitory antibody and by supplying normal protease. For patients with disease refractory to PEX, there is no standardized treatment. Limited and sporadic success with different therapies (vincristine sulfate. prostacyclin. intravenous immunoglobulins. splenectomy) has been described. We report the case of a woman who developed refractory disease after an initial response to PEX and despite a very high number of PEX procedures performed. Low activity (<5%) of serum vWF-cleaving protease and a low level of protease inhibitor were documented. The patient had a slow but sustained response when oral cyclosporine was administered concomitantly with PEX, which was slowly tapered. The activity of serum vWF-cleaving protease normalized. At relapse, treatment with cyclosporine, added after the failure of steroids and PEX, led to a lasting response. It is possible that in some cases cyclosporine therapy must be of particularly long duration before being considered ineffective. (C) 2002 The Japanese Society of Hematology.
引用
收藏
页码:284 / 286
页数:3
相关论文
共 17 条
[1]  
Bachman WR, 1996, AM J HEMATOL, V51, P93, DOI 10.1002/(SICI)1096-8652(199601)51:1<93::AID-AJH16>3.0.CO
[2]  
2-C
[3]  
BOBBIOPALLAVICINI E, 1994, EUR J HAEMATOL, V52, P222
[4]   CYCLOSPORINE-ASSOCIATED THROMBOTIC THROMBOCYTOPENIC PURPURA FOLLOWING LIVER-TRANSPLANTATION - SUCCESSFUL TREATMENT WITH PLASMA-EXCHANGE [J].
DZIK, WH ;
GEORGI, BA ;
KHETTRY, U ;
JENKINS, RL .
TRANSPLANTATION, 1987, 44 (04) :570-572
[5]   Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome [J].
Furlan, M ;
Robles, R ;
Galbusera, M ;
Remuzzi, G ;
Kyrle, PA ;
Brenner, B ;
Krause, M ;
Scharrer, I ;
Aumann, V ;
Mittler, U ;
Solenthaler, M ;
Lämmle, B .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (22) :1578-1584
[6]  
GABLE PS, 1993, BLOOD, V82, pA604
[7]  
Hand JP, 1998, BRIT J HAEMATOL, V100, P597
[8]   MICROANGIOPATHY FOLLOWING ALLOGENEIC MARROW TRANSPLANTATION - ASSOCIATION WITH CYCLOSPORINE AND METHYLPREDNISOLONE FOR GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS [J].
KALHS, P ;
BRUGGER, S ;
SCHWARZINGER, I ;
GREINIX, HT ;
KEIL, F ;
KYRLE, PA ;
KNOBL, P ;
SCHNEIDER, B ;
HOCKER, P ;
LINKESCH, W ;
LECHNER, K .
TRANSPLANTATION, 1995, 60 (09) :949-957
[9]   CYCLOSPORINE FOR THROMBOTIC THROMBOCYTOPENIC PURPURA [J].
KIERDORF, H ;
MAURIN, N ;
HEINTZ, B .
ANNALS OF INTERNAL MEDICINE, 1993, 118 (12) :987-988
[10]   Thrombotic microangiopathy following allogeneic bone marrow transplantation is associated with intensive graft-versus-host disease prophylaxis [J].
Paquette, RL ;
Tran, L ;
Landaw, EM .
BONE MARROW TRANSPLANTATION, 1998, 22 (04) :351-357